Canada markets closed

Wuhan YZY Biopharma Co., Ltd. (2496.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
7.4500.000 (0.00%)
At close: 11:51AM HKT
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
Total Revenue
0
0
0
0
Operating Expenses
Research Development
155,054
155,054
157,329
112,893
Selling General and Administrative
22,311
22,311
20,525
8,874
Total Operating Expenses
190,050
190,050
187,375
134,967
Operating Income or Loss
-190,050
-190,050
-187,375
-134,967
Interest Expense
2,388
2,388
2,468
14,972
Income Before Tax
-191,702
-191,702
-188,866
-148,518
Income Tax Expense
0
0
0
0
Income from Continuing Operations
-191,702
-191,702
-188,866
-148,518
Net Income
-191,702
-191,702
-188,866
-148,518
Net Income available to common shareholders
-191,702
-191,702
-188,866
-148,518
Basic EPS
-0.98
-
-0.98
-0.77
Diluted EPS
-0.98
-
-0.98
-0.77
Basic Average Shares
193,001
-
193,001
193,001
Diluted Average Shares
193,001
-
193,001
193,001